ViiV Boosted By Early GEMINI Data, But More Details Wanted
Executive Summary
ViiV Healthcare has positive early pivotal data for its second two-drug regimen for HIV, but more reassurance is needed on the relative rates of virologic suppression in patients with low and high viral loads, as well as on the long-term risk of virologic failure. The combination should help form ViiV's defense against rival Gilead and its new triple combination Biktarvy.
You may also be interested in...
ViiV Steals A March On Gilead with HIV Doublet Data
ViiV Healthcare intends to seek regulatory approval for a fixed-dose combination of Tivicay and Epivir later this year based on positive 48-week data from the GEMINI studies in treating HIV that analysts say have helped to lift key uncertainties about the treatment and boost ViiV's competitive position versus key rival Gilead Sciences, which has favored triplet therapy.
ViiV Two-Drug HIV Pill Juluca Close To Europe Okay
The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.